Illumina, Inc. vs VanEck Vietnam ETF — how do they compare? Illumina, Inc. trades at $190.93 (market cap $29.12B), while VanEck Vietnam ETF trades at $17.81. The key difference: Illumina, Inc. is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | VNM | |
|---|---|---|
Market Cap | $29.12B | — |
Sector | Health | Sector/Thematic |
52-Week High | $205.10 | $19.80 |
52-Week Low | $91.00 | $16.34 |
Enterprise Value | $30.48B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
VNM trades at $17.73, up 0.51% today, with a bullish technical signal driven by positive momentum indicators. The stock faces immediate resistance at $18, with support at $17. Recent news highlights Vietnam's economic challenges, including power grid strain and foreign capital outflows from Asian equities, potentially impacting the ETF's holdings.
Outlook remains cautious due to macroeconomic headwinds in Vietnam and underperformance relative to emerging markets. Investment opportunity hinges on FTSE Russell's EM reclassification attracting foreign inflows, but risks include heatwave-induced infrastructure stress and regional capital rotation away from AI-exposed markets.
Trailing returns across standard periods
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →